BRPI0800485B8 - recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method - Google Patents

recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method

Info

Publication number
BRPI0800485B8
BRPI0800485B8 BRPI0800485A BRPI0800485A BRPI0800485B8 BR PI0800485 B8 BRPI0800485 B8 BR PI0800485B8 BR PI0800485 A BRPI0800485 A BR PI0800485A BR PI0800485 A BRPI0800485 A BR PI0800485A BR PI0800485 B8 BRPI0800485 B8 BR PI0800485B8
Authority
BR
Brazil
Prior art keywords
leishmaniasis
viral vectors
recombinant viral
vaccine composition
vaccination
Prior art date
Application number
BRPI0800485A
Other languages
Portuguese (pt)
Inventor
Paula Salles Moura Fernandes Ana
Da Fonseca Guimarães Flavio
Bruna Romero Oscar
Tostes Gazzinelli Ricardo
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0800485A priority Critical patent/BRPI0800485B8/en
Priority to MX2010007876A priority patent/MX2010007876A/en
Priority to PCT/BR2009/000014 priority patent/WO2009089605A1/en
Priority to CN201710930134.7A priority patent/CN108014330A/en
Priority to CN200980105562XA priority patent/CN102036681A/en
Publication of BRPI0800485A2 publication Critical patent/BRPI0800485A2/en
Publication of BRPI0800485A8 publication Critical patent/BRPI0800485A8/en
Publication of BRPI0800485B1 publication Critical patent/BRPI0800485B1/en
Publication of BRPI0800485B8 publication Critical patent/BRPI0800485B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

vetores virais recombinantes, composição vacinal para leishmaniose e método profilático/terapêutico de vacinação para leishmaniose. a presente invenção diz respeito a vetores virais recombinantes que expressam o antígeno a2 de leishmania e composições vacinais úteis para serem utilizadas como vacina contra leishmaniose. a invenção ainda revela um método de vacinação dose-reforço (prime-boost) que utiliza vetores adenovirais e poxvirais para a imunização de mamíferos contra leishmaniose. tal método permite a distinção sorológica entre indivíduos vacinados e infectados por meio de testes de elisa ou imunofluorescência convencionais empregando antígenos de formas promastigotas de leishmania.recombinant viral vectors, vaccine composition for leishmaniasis and prophylactic/therapeutic method of vaccination for leishmaniasis. the present invention relates to recombinant viral vectors expressing the a2 antigen of leishmania and vaccine compositions useful to be used as a vaccine against leishmaniasis. the invention further discloses a dose-boost (prime-boost) vaccination method that uses adenoviral and poxviral vectors to immunize mammals against leishmaniasis. such method allows the serological distinction between vaccinated and infected individuals by means of conventional elisa or immunofluorescence tests using antigens from promastigote forms of leishmania.

BRPI0800485A 2008-01-17 2008-01-17 recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method BRPI0800485B8 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0800485A BRPI0800485B8 (en) 2008-01-17 2008-01-17 recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method
MX2010007876A MX2010007876A (en) 2008-01-17 2009-01-16 Recombinant viral vectors and vaccine composition for leishmaniasis.
PCT/BR2009/000014 WO2009089605A1 (en) 2008-01-17 2009-01-16 Recombinant viral vectors and vaccine composition for leishmaniasis
CN201710930134.7A CN108014330A (en) 2008-01-17 2009-01-16 Recombinant viral vector and vaccine combination for leishmaniasis
CN200980105562XA CN102036681A (en) 2008-01-17 2009-01-16 Recombinant viral vectors and vaccine composition for leishmaniasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800485A BRPI0800485B8 (en) 2008-01-17 2008-01-17 recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method

Publications (4)

Publication Number Publication Date
BRPI0800485A2 BRPI0800485A2 (en) 2009-09-01
BRPI0800485A8 BRPI0800485A8 (en) 2018-04-17
BRPI0800485B1 BRPI0800485B1 (en) 2021-03-02
BRPI0800485B8 true BRPI0800485B8 (en) 2021-05-25

Family

ID=40885010

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0800485A BRPI0800485B8 (en) 2008-01-17 2008-01-17 recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method

Country Status (4)

Country Link
CN (2) CN108014330A (en)
BR (1) BRPI0800485B8 (en)
MX (1) MX2010007876A (en)
WO (1) WO2009089605A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2795149B2 (en) 2020-06-08 2022-07-04 Univ Madrid Complutense SYNTHETIC MULTIEPITOPIC CHIMERA AS A VACCINE AND TREATMENT AGAINST LEISHMANIOSIS IN MAMMALS
CN113337542A (en) * 2021-06-10 2021-09-03 山西大学 Human replication-defective recombinant adenovirus vector for efficiently expressing Leishmania PEPCK

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502091A (en) * 1993-09-03 1997-03-04 マックギル ユニヴァーシティー Leishmania genes and proteins that are specifically expressed
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6638517B2 (en) * 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2109189B1 (en) * 1996-03-14 1998-05-16 Iberica Cyanamid VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR USE IN THE FORMULATION OF VACCINES.
WO2002078735A2 (en) * 2001-03-29 2002-10-10 Mcgill University Leishmania vaccines
EP1771571A2 (en) * 2004-07-30 2007-04-11 Targeted Genetics Corporation Recombinant aav based vaccine methods

Also Published As

Publication number Publication date
BRPI0800485A8 (en) 2018-04-17
CN108014330A (en) 2018-05-11
BRPI0800485B1 (en) 2021-03-02
WO2009089605A1 (en) 2009-07-23
BRPI0800485A2 (en) 2009-09-01
CN102036681A (en) 2011-04-27
MX2010007876A (en) 2011-03-03

Similar Documents

Publication Publication Date Title
EA201291105A1 (en) ORAL VACCINE CONTAINING ANTIGEN AND AGONIST OF TOLL-LIKE RECEPTOR
EA200701786A1 (en) POLYVALENT ANTIGRIPOSE IMMUNOGENOUS COMPOSITION
EA200701128A1 (en) Recombinant strains of BCG, possessing enhanced ability to release from endosomes.
BR112014011229A2 (en) compositions and methods for the treatment of cytomegalovirus
BRPI0518146A (en) parts kit, use of a recombinant defective adenovirus in replication, and method of vaccinating a mammal for malaria infection
ATE527281T1 (en) VACCINES AGAINST AIDS COMPRISING CMV/R NUCLEIC ACID CONSTRUCTS
BR112015009070A2 (en) fusion protein or antigen cocktail; use of a fusion protein or cocktail of antigens; vaccine; and method for immunizing an animal, including a human, against tuberculosis caused by virulent microbacteria
UY31285A1 (en) VACCINES
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
CO6210756A2 (en) THE TIMICA CANINA STROMAL LYMPHOPOYETINE PROTEIN AND USES OF THE SAME
AR093712A1 (en) IMMUNOGEN COMPOSITION, VACCINE, USE AND PROCEDURE FOR PREVENTION OR TREATMENT
BRPI1007721B1 (en) vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66
CL2017003224A1 (en) Vaccine against foot-and-mouth disease virus (fmdv) of recombinant modified vaccinia ankara virus (mva)
WO2006050219A3 (en) Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
NO20074855L (en) Use of a modified pox virus for the rapid induction of immunity to a pox virus or other infectious agents
UA110024C2 (en) VACCINE VECTOR AND METHOD OF IMMUNE IMPROVEMENT
CO2019000214A2 (en) Vaccine against infectious bronchitis virus
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
PE20081687A1 (en) FUSION PROTEIN
MX2016001695A (en) Combination immunogenic compositions.
BR112012029633A8 (en) PARAPOXVIRUS VECTORS CONTAINING RABBIT VIRUS ANTIGEN.
BRPI0800485B8 (en) recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method
MX2019007924A (en) Influenza vaccines.
AR093530A1 (en) VACCINATION ASSISTANT, PREPARATION, AND VACCINES CONTAINING IT
EA201200538A1 (en) ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B03H Publication of an application: rectification [chapter 3.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF